Leslie S. Sloan, PhD is SVP of Development and Operations at PanTher Therapeutics. As seasoned global executive, Leslie has demonstrated a proven ability to drive execution and delivery of drug development programs.
Her broad profession experience includes executive leadership, strategic and operational program and portfolio leadership, BLA/NDA submissions and approvals, and R&D strategy and execution across multiple therapeutic areas (metabolic disease, oncology, cardiovascular) and modalities (small molecules, peptides, biologics). Leslie and her teams have been instrumental to 15 successful new or supplemental market authorization submissions in the US, EU and Asia.
Prior to joining PanTher Therapeutics, Leslie was the Chief Operating Officer of Aeglea Biotherapeutics, a human enzyme therapeutics company. During her time at Aeglea, Leslie oversaw portfolio programs from discovery through clinical development to achieve scientific, medical, and financial objectives.
Previously, Leslie held several global leadership roles at Ipsen and Pfizer. While at Ipsen, she provided strategic and operational leadership for a global R&D portfolio focused on cancer, neuroscience, and rare disease. She also delivered cross-functional leadership for clinical program teams, spanning from IND enabling through Ph1, Ph2, and Ph3 phases of development and life cycle management.
In addition, Leslie is an effective leader who fosters cross-functional, empowered teams and develops people, resulting in a track record of hiring and developing talented, collaborative and successful global teams.
Leslie holds PhD and MS degrees in Bioorganic Chemistry from Yale University and a BS in Chemistry and Medical Biology from Southeastern Oklahoma State University.